Pharming Group N.V. Reports Q1 2025 Results
Ticker: PHAR · Form: 6-K · Filed: Mar 20, 2025 · CIK: 1828316
| Field | Detail |
|---|---|
| Company | Pharming Group N.V. (PHAR) |
| Form Type | 6-K |
| Filed Date | Mar 20, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: financial-results, 6-K, pharmaceuticals
TL;DR
Pharming Group N.V. dropped Q1 2025 results on 3/20/25. Check the 6-K for details.
AI Summary
Pharming Group N.V. announced its first quarter 2025 financial results on March 20, 2025. The company, headquartered in Leiden, The Netherlands, is a pharmaceutical preparations firm.
Why It Matters
This filing provides investors with an update on Pharming Group's financial performance and operational status for the first quarter of 2025.
Risk Assessment
Risk Level: low — This is a routine financial results filing with no immediately apparent negative or positive catalysts.
Key Players & Entities
- Pharming Group N.V. (company) — Registrant
- March 20, 2025 (date) — Filing Date
- Leiden, The Netherlands (location) — Company Headquarters
FAQ
What is the primary business of Pharming Group N.V.?
Pharming Group N.V. is in the Pharmaceutical Preparations industry, SIC code 2834.
When was this Form 6-K filed?
This Form 6-K was filed on March 20, 2025.
What is the company's principal executive office address?
The company's principal executive offices are located at Darwinweg 24, 2333 CR Leiden, The Netherlands.
Does Pharming Group N.V. file annual reports under Form 20-F?
Yes, Pharming Group N.V. indicates it files annual reports under Form 20-F.
What exhibit is furnished with this Form 6-K?
Exhibit 99.1, a press release of Pharming Group N.V. dated March 20, 2025, is furnished with this Form 6-K.
Filing Details
This Form 6-K (Form 6-K) was filed with the SEC on March 20, 2025 regarding Pharming Group N.V. (PHAR).